A carregar...
Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Non-small cell lung cancer (NSCLC) patients that harbor epidermal growth factor receptor (EGFR) mutations benefit from receiving an EGFR-tyrosine kinase inhibitor (TKI); however, post-progression survival (PPS) after EGFR-TKI treatment has not been sufficiently studied.We retrospectively reviewed th...
Na minha lista:
Main Authors: | , , , , , , |
---|---|
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
Public Library of Science (PLoS)
2015-01-01
|
Colecção: | PLoS ONE |
Acesso em linha: | http://europepmc.org/articles/PMC4532435?pdf=render |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|